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Abstract: The oral inflammatory diseases are divided into two types: acute and chronic inflammatory
diseases. In this review, we summarize the biological efficacy of herbal medicine, natural products,
and their active ingredients against acute and chronic inflammatory diseases in the oral region,
especially stomatitis and periodontitis. We review the effects of herbal medicines and a biscoclaurin
alkaloid preparation, cepharamthin, as a therapy against stomatitis, an acute inflammatory disease.
We also summarize the effects of herbal medicines and natural products against periodontitis,
a chronic inflammatory disease, and one of its clinical conditions, alveolar bone resorption. Recent
studies show that several herbal medicines such as kakkonto and ninjinto reduce LPS-induced PGE2
production by human gingival fibroblasts. Among herbs constituting these herbal medicines, shokyo
(Zingiberis Rhizoma) and kankyo (Zingiberis Processum Rhizoma) strongly reduce PGE2 production.
Moreover, anti-osteoclast activity has been observed in some natural products with anti-inflammatory
effects used against rheumatoid arthritis such as carotenoids, flavonoids, limonoids, and polyphenols.
These herbal medicines and natural products could be useful for treating oral inflammatory diseases.
Keywords: inflammatory disease; stomatitis; periodontitis; anti-osteoclast activity; cepharanthin;
herbal medicine; natural product; arachidonic acid cascade
1. Introduction
Oral inflammatory disease is a general term for the inflammatory lesions developed in oral mucosa.
The pathogenesis of oral inflammatory diseases is non-uniform due to the involvement of various
factors—such as external and mechanical stimuli, the presence of microorganisms, and the overall
physical conditions—that play a role in the onset of inflammation. There is a wide range of variations
in the aspect of oral inflammatory diseases, and the aspect is unequal. Therefore, we construed the
oral inflammatory diseases as a symptom of inflammation, and categorized them into acute and
chronic inflammatory diseases. In the oral region, the representative example of acute inflammatory
diseases is stomatitis (also named as oral mucositis), and that of chronic inflammatory diseases is
periodontitis. Several Japanese herbal medicines (also known as kampo medicines) are clinically
used for the treatment of inflammatory diseases. Recent reviews have summarized the therapeutic
application of herbal medicines for oral diseases such as stomatitis and periodontitis [1]. For example,
hangeshashinto (TJ-14) is used for inflammatory diseases such as acute or chronic gastrointestinal
catarrh, nervous gastritis and stomatitis.
Medicines 2018, 5, 122; doi:10.3390/medicines5040122 www.mdpi.com/journal/medicines
Medicines 2018, 5, 122 2 of 24
In this review, we aim to summarize the biological efficacy of herbal medicine, natural products,
and their active ingredients against acute and chronic inflammatory diseases in the oral region,
especially stomatitis and periodontitis.
2. Biological Efficacy of Natural Products against Acute Inflammatory Disease: Stomatitis
2.1. Stomatitis (Oral Mucositis)
Stomatitis is an inflammatory condition of the oral and oropharyngeal mucosa with both pain
and ulcers in severe cases. The causes of stomatitis is classified into (1) bacterial or viral infection,
(2) chemotherapy and/or radiation for the treatment of cancers, (3) autoimmune disease (such as lichen
planus and pemphigus vulgaris), and (4) unknown (such as recurrent aphthous stomatitis). Recurrent
aphthous stomatitis is a common condition characterized by the repeated formation of benign and
non-contagious mouth ulcers (aphthae). However, the cause of aphthous stomatitis is still unknown.
2.2. Effect of Hangeshashinto on Stomatitis
Recently, clinical administration of herbal medicine, such as the treatment of recurrent aphthous
stomatitis, has been increasing in Japan. Herbal medicines are chosen according to the patient’s
condition, called “sho” (pattern), for example “excess pattern” or “deficiency pattern.” Among the
herbal medicines, some products such as hangeshashinto (TJ-14), orengedokuto (TJ-15), orento (TJ-120),
inchinkoto (TJ-135), byakkokaninjinto (TJ-34), juzentaihoto (TJ-48), and shosaikoto (TJ-9) are selected in
the treatment against oral inflammatory diseases, including recurrent aphthous stomatitis, according
to the patient’s pattern [2]. In addition, it seems that hangeshashinto is considered effective in the
treatment of stomatitis caused by anti-tumor agents and radiation therapy [2].
In a preliminary study, rinsing with hangeshashinto reduced the grade of stomatitis [by Common
Terminology Criteria for Adverse Events (CTCAE) version 4.0, National Cancer Institute, Bethesda,
MD] [3]. Moreover, in a double-blind, placebo-controlled, random, phase II study, the rinsing of the
oral cavity with hangeshashinto showed a trend to reduce the risk of chemotherapy-induced stomatitis
in patients with gastric cancer [4]. In this study, hangeshashinto reduced the risk of grade 1 stomatitis
but did not reduce those of more than grade 2 [4]. In a retrospective study, rinsing and gargling with
hangeshashinto prevented grade 3/4 stomatitis induced by (chemo)radiation in patients with head
and neck cancers (odds ratio = 0.21, 95% CI: 0.045–0.780, hangeshashinto: n = 27, placebo: n = 32) [5].
In addition, hangeshashinto also improved the rates of the treatment of stomatitis [5].
In an animal model, free intake of diet mixed with 2% hangeshashinto prevented radiation-induced
mucositis within the buccal mucosa in hamsters [6]. In addition, hangeshashinto inhibited
the infiltration of neutrophils and COX-2 expression in irradiated buccal mucosa [6]. Moreover,
in an in vitro study using oral keratinocytes, hangeshashinto was suggested to be effective in the
treatment of chemotherapy-induced stomatitis [7]. As just described, hangeshashinto is effective for
the improvement of stomatitis although there is little evidence in in vivo and in vitro studies.
2.3. Effect of Cepharanthin R© on Stomatitis
A biscoclaurin alkaloid preparation, Cepharanthin R© (CE), has also been used for the cure of
oral mucosal disease, such as recurrent aphthous stomatitis, leukoplakia, and oral lichen planus.
CE is a drug product, prepared from extracts of Stephania cephalantha Hayata, and has been widely
used for several decades to treat a range of acute and chronic diseases in Japan [8,9]. As CE is
reported to elicit an anti-inflammatory effect and increase blood stem cell count, immuno-enhancing
effects, and anti-allergic properties, it has seen clinical application against inflammatory diseases as
well as post-radiation-therapy leukocytopenia, pit viper bite, alopecia areata, and bronchial asthma.
Nakase et al. reported that the rate of excellent or moderate efficacy was 100% for aphthous stomatitis
and 25.0% for reducing the size of oral lichen planus, and its efficacy for glossodynia was 83.4% by
CE treatment with gargle-internal use (15 mg/day) for two weeks [10]. Moreover, Saki et al. also
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reported—regarding the efficacy of CE against these oral mucosal diseases— that the improvement
rate by oral administration of CE (20 mg/day) for 4 weeks or more was 83.3% for aphthous stomatitis,
87.0% for oral lichen planus, 77.8% for glossodynia, and 80.0% for leukoplakia. In this case, they
evaluated the clinical response and rated according to the assessment points such as the degrees of
pain, ulcer, erosion, and erythema [11]. Taken together, it is considered that CE is beneficial in the cure
of aphthous stomatitis, according to previous clinical reports [12].
CE is a biscoclaurin alkaloid preparation, and the main active ingredients are four alkaloids:
cepharanthine (26%), isotetrandrine (32%), berbamine (13%), and cycleanine (10%) (Figure 1). Using
a mixture of these four active ingredients in CE exhibits almost an equal effect as that of CE [13,14].
Functional mechanisms of CE and its main active ingredients for inflammatory diseases have been
reported in previous studies. For example, CE reduced the production of superoxide anion (O−2 ) by
neutrophils [15] and by macrophages [16], and decreased the levels of several types of reactive oxygen
species (O−2 , H2O2, OH
·) by behaving as a reactive oxygen species (ROS) scavenger [17].
Figure 1. The structures of active ingredients in Cepharanthin R©.
According to previous literatures corresponding to the application of the four main active
ingredients, cepharanthine was reported to inhibit the synthesis of leukotriene B4 through the
reduction of arachidonic acid release [18]. Moreover, each of the four main active ingredients reduced
NO production by activated macrophages [19]. However, there was a difference in the efficacy
against the O−2 and TNF-α production among main active ingredients; the efficacy of cepharanthine
and isotetrandrine seemed to be more than that of berbamine and cycleanine in the reduction
of O−2 production by neutrophils [20]. It was also reported that cepharanthine, isotetrandrine,
and cycleanine, but not berbamine, significantly reduced the level of TNF-α or acute lethal toxicity
induced by lipopolysaccaride (LPS) in mice [13,21]. Additionally, Matsuno et al. reported that
the decreasing effect of O−2 production through neutrophil stimulation by arachidonic acid and
N-formylmethionine-leucyl-phenylalanine (FMLP) was more evident in cepharanthine than in
opsonized zymogen [20]. This finding indicates the cell membrane to be a possible operating point
of CE, and this hypothesis is supported in the following study by Sugiyama et al., who reported that
cepharanthine could inhibit histamine release from mast cells through the stabilization of the membrane
by decreasing membrane fluidity via interaction with the lipid bilayer of the cell membrane [22].
Interestingly, the pharmacological actions of CE on living bodies vary depending on the
method of administration. We reported that the single injection of CE reduced the LPS-induced
histidine decarboxylase (HDC) activity, although contrastingly, LPS-induced HDC activity in mice
spleens increased after consecutive administration of CE [23]. Moreover, it was considered that mast
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cell was closely associated with this reduction of HDC activity, because LPS-induced HDC activity in
mast-cell-deficient mice increased, but decreased in normal mice following a single administration of
CE [23]. CE has immuno-enhancing effects as well as anti-inflammatory effects. The inhibition of mast
cells may be closely related to the difference of CE action.
Conclusively, CE is considered to be an effective treatment of oral inflammatory diseases, such as
recurrent aphthous stomatitis, through the reduction of various function in immunocytes closely
related to inflammation.
3. Biological Efficacy of Natural Products against Chronic Inflammatory Disease; Periodontitis
3.1. Periodontitis
Periodontal disease (periodontitis) comprises a group of infections that leads to inflammation of
the gingiva and destruction of periodontal tissues, and is accompanied by alveolar bone loss in severe
clinical cases. The tissue destruction is the result of activation of the host’s immuno-inflammatory
response to virulent factors such as LPS and peptidoglycan. In inflammatory responses and
tissue degradation, prostaglandin E2 (PGE2), interleukin (IL)-6, and IL-8 play important roles.
As PGE2 has several functions in vasodilation, the enhancement of vascular permeability and pain,
and osteoclastogenesis induction, PGE2 participates in inflammatory responses and alveolar bone
resorption in periodontitis [24].
Generally, periodontitis is a chronic inflammation, and the elimination of these virulent factors
by initial preparation is very important for the treatment of periodontitis. However, during the
acute advanced stage, non-steroidal anti-inflammatory drugs (NSAIDs) are administrated to improve
gingival inflammation. In fact, many studies have demonstrated that systemic administration of acid
NSAIDs prevented gingival inflammation and alveolar bone resorption in animals and humans [25].
However, acid NSAIDs are well known to have side effects such as gastrointestinal dysfunction
and bronchoconstriction. Therefore, the usage of alternative agents is necessary for patients with
gastrointestinal ulcer or bronchial asthma. Previously, we suggested that several herbal medicines are
effective for the improvement of periodontitis. In this review, we focused on the anti-inflammatory
effects of herbal medicines on mainly periodontitis —in particular, about the effects on human gingival
fibroblasts (HGFs). In addition, we summarized the effects of ingredients in herbs and their mechanism
against arachidonic acid cascade.
Here, we will explain the importance of HGFs in the study of periodontitis. (1) HGFs are
the most prominent cells in periodontal tissue. LPS-treated HGFs produce inflammatory chemical
mediators, such as PGE2, and inflammatory cytokines such as IL-6 and IL-8. (2) More importantly,
unlike macrophages, HGFs continue to produce PGE2 [26], IL-6, and IL-8 [27] in the presence of LPS.
From these findings, the large amount of chemical mediators and cytokines derived from HGFs may be
contained in periodontal tissues. Therefore, we believe that examining the effects of pharmaceuticals
on HGFs is needed in the study of periodontitis.
3.2. Brief Summary of Arachidonic Acid Cascade
At first, we explain arachidonic acid cascade briefly, focusing on sites of action for herbs and
ingredients. PGE2 is produced by arachidonic acid cascade (Figure 2). Phospholipids in plasma
membrane are digested by phospholipase A2 (PLA2), producing arachidonic acid. Cyclooxygenases
(COXs) convert arachidonic acid into PGH2, and thereafter PGE synthase converts into PGE2.
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Figure 2. Simplified schema of arachidonic acid cascade.
PLA2 is the most upstream enzyme in the arachidonic acid cascade and releases arachidonic
acid from the plasma membrane. PLA2 forms a superfamily and is classified into cytosolic PLA2
(cPLA2), calcium-independent PLA2 (iPLA2), secretory PLA2 (sPLA2), and others [28]. Among
these isoforms, cPLA2 is the primary isoform in HGFs from the results using PLA2 inhibitors [29].
cPLA2 activity is directly regulated by extracellular signal-regulated kinase (ERK). The active form of
ERK (phosphorylated ERK) phosphorylates Ser505 of cPLA2 and activates cPLA2 [30–32]. Therefore,
the suppression of ERK phosphorylation leads to the suppression of cPLA2 activation and the reduction
of PGE2 production [30–32]. In contrast, annexin1, also named as lipocortin, is an anti-inflammatory
mediator produced by steroidal anti-inflammatory drugs (SAIDs) that inhibits PLA2 activity [33,34].
COX is classified into COX-1 and COX-2. COX-1 is constitutive expressed at low level, and is
involved in normal functions such as protection of gastric mucosa. In contrast, COX-2 is induced
by the various stimuli such as LPS and peptidoglycan, and involved in inflammatory response.
The expression of COX-2 is upregulated by NF-κB. The reduction of PGE2 by anti-inflammatory
drugs is one of the important mechanisms. Acid NSAIDs inhibit both COX-1 and COX-2 activities.
The inhibition of COX-2 improve inflammatory response, while the inhibition of COX-1 causes gastric
irritation. SAIDs also have powerful anti-inflammatory effects, and inhibit NF-κB activity and suppress
COX-2 expression.
Recently, protein kinase A (PKA) pathway is reported to regulate LPS-induce PGE2 production in
HGFs [35]. PKA inhibitor (H-89) reduced LPS-induced PGE2 production in a concentration-dependent
manner. In contrast, PKA activator (dibutyryl cAMP; dbcAMP) and drugs which increased
intracellular cAMP (adrenaline and aminophylline) increased LPS-induced PGE2 production in a
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concentration-dependent manner. However, the effects of PKA pathway on arachidonic acid cascade
have not been examined in this report [35].
3.3. Effect of Herbal Medicines on Periosontal Disease
Similar to NSAIDs, several herbal medicines also reduce PGE2 production. Examples of herbal
medicine which have been reported to reduce PGE2 production in in vitro and/or animal models are
shown in Table 1. In particular, we reported that kakkonto (TJ-1), shosaikoto (TJ-9), hangeshashinto
(TJ-14), shinbuto (TJ-30), ninjinto (TJ-32), and orento (TJ-120) reduced LPS-induced PGE2 production
using HGFs [36–40]. Other groups have also demonstrated that several herbal medicines reduced PGE2
production using human periodontal ligament cells [41], human monocytes [42], mouse macrophage
RAW264.7 cells [43,44], human oral keratinocytes [7], and animals [45–48].
Table 1. Japanese traditional herbal medicines which are reported to reduce PGE2 production.
Herbal Medicine Cells or Animal References
kakkonto (TJ-1) HGFs [36]
shosaikoto (TJ-9) HGFs [37]
human monocytes [42]
mouse [45]
hangeshashinto (TJ-14) HGFs [38,41]
human periodontal ligament cells [41]
human oral keratinocytes [7]
rat [46–48]
shinbuto (TJ-30) HGFs [39]
ninjinto (TJ-32) HGFs [39]
rikkosan (TJ-110) RAW264.7 [43]
saireito (TJ-114) RAW264.7 [44]
orento (TJ-120) HGFs [40]
We introduce briefly the effects and mechanisms of herbal medicines on periodontitis in clinical,
animal, and/or in vitro studies. Moreover, in this section, we will demonstrate the effects of herbal
medicines on the reduction of PGE2 in HGFs. From our data, the mechanisms of these herbal medicines
on arachidonic acid cascade are divided into three groups as follows.
• Shosaikoto (TJ-9) inhibited COX-2 activity and suppressed COX-2 expression, but did not
alter cPLA2 expression (the effects on annexin1 expression and ERK phosphorylation were
not examined) [37]. Hangeshashinto (TJ-14) inhibited both COX-1 and COX-2 activities,
and suppressed cPLA2 and COX-2 expressions and ERK phosphorylation [38]. Therefore, these
herbal medicines are suggested to inhibit arachidonic acid cascade at multiple points.
• Shinbuto (TJ-30) and ninjinto (TJ-32) enhanced annexin1 expression, but did not alter ERK
phosphorylation and COX activity [39]. However, the contribution of enhancement of annexin1
expression is considered to be small because shokyo, which is the main herb in shinbuto to reduce
PGE2 production, did not affect annexin1 expression.
• Kakkonto (TJ-1) suppressed ERK phosphorylation, but neither inhibited COXs activities nor
suppressed the expression of molecules in arachidonic acid cascade [36]. In addition,
orento (TJ-120) suppressed ERK phosphorylation, but neither inhibited COXs activities nor
suppressed the expression of molecules in arachidonic acid cascade, but rather increased COX-2
expression [40]. However, its contribution in the suppression of ERK phosphorylation is
considered to be small as described at keihi (Cinnamomi Cortex). Indeed, we did not examine the
direct effect of herbal medicines on cPLA2 activity. Nevertheless, we consider that these herbal
medicines inhibit cPLA2 activity and that this effect is due to shokyo (Zingiberis Rhizoma) and
kankyo (Zingiberis Processum Rhizoma) as described below.
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3.4. Effect of Herbs on Arachidonic Acid Cascade
Next, we will demonstrate the experimental results at the herb level. The ingredients in the
formula of herbal medicines that were used are shown in Tables 2–7. In our experiments at the herb
level, shokyo (Zingiberis Rhizoma), kankyo (Zingiberis Processum Rhizoma), kanzo (Glycyrrhizae Radix),
and keihi (Cinnamomi Cortex) reduced PGE2 production (Figures 3 and 4) [29,39]. We summarized
major ingredients in herbs and their mechanism against arachidonic acid cascade in Table 8. In addition
to these four herbs, ogon (Scutellariae Radix), and oren (Coptidis Rhizoma) are shown in Table 8 because
ogon (included in shosaikoto and hangeshashinto) and oren (included in hangeshashinto and orento)
also have several bioactive ingredients such as flavonoids, saponin, and chalcones. We will describe
the effects and mechanisms of these herbs, particularly shokyo and kankyo, on arachidonic cascade.
Figure 3. The effect of herbs in kakkonto (TJ-1) on PGE2 production: This figure is cited from Ara and
Sogawa [29] (CC-BY-4.0) and modified for this review.
Figure 4. The effect of herbs in shinbuto (TJ-30) and ninjinto (TJ-32) on PGE2 production: This figure
is cited from Ara and Sogawa [39] (CC-BY-4.0) and modified for this review. (A): Effect of each herb,
(B): Concentration-dependent effects of shokyo and kankyo.
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Table 2. The ingredients in the kakkonto (TJ-1) formula.
Japanese Name Scientific Name Amount Amount *(Latin Name) (g) (g/g of Product)
kakkon Pueraria lobata Ohwi 4.0 0.111
(Puerariae Radix)
taiso Ziziphus jujuba Miller var. inermis Rehder 3.0 0.083
(Zizyphi Fructus)
mao Ephedra sinica Stapf 3.0 0.083
(Ephedrae Herba) Ephedra intermedia Schrenk et C.A.Meyer
Ephedra equisetina Bunge
kanzo Glycyrrhiza uralensis Fischer 2.0 0.056
(Glycyrrhizae Radix) Glycyrrhiza glabra Linné
keihi Cinnamomum cassia Blume 2.0 0.056
(Cinnamomi Cortex)
shyakuyaku Paeonia lactiflora Pallas 2.0 0.056
(Paeoniae Radix)
shokyo Zingiber officinale Roscoe 2.0 0.056
(Zingiberis Rhizoma)
total 18.0 0.500
* 7.5 g of kakkonto product contains 3.75 g of a dried extract of the mixed crude drugs.
Table 3. The ingredients in the shosaikoto (TJ-9) formula.
Japanese Name Scientific Name Amount Amount *(Latin Name) (g) (g/g of Product)
saiko Bupleurum falcatum Linné 7.0 0.175
(Bupleuri Radix)
hange Pinellia ternata Breitenbach 5.0 0.125
(Pinelliae tuber)
ogon Scutellaria baicalensis Georgi 3.0 0.075
(Scutellariae radix)
taiso Ziziphus jujuba Miller var. inermis Rehder 3.0 0.075
(Zizyphi Fructus)
ninjin Panax ginseng C.A. Meyer 3.0 0.075
(Ginseng Radix)
kanzo Glycyrrhiza uralensis Fischer 2.0 0.050
(Glycyrrhizae Radix) Glycyrrhiza glabra Linné
shokyo Zingiber officinale Roscoe 1.0 0.025
(Zingiberis Rhizoma)
total 24.0 0.600
* 7.5 g of shosaikoto product contains 4.5 g of a dried extract of the mixed crude drugs.
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Table 4. The ingredients in the hangeshashinto (TJ-14) formula.
Japanese Name Scientific Name Amount Amount *(Latin Name) (g) (g/g of Product)
hange Pinellia ternata Breitenbach 5.0 0.162
(Pinelliae tuber)
ogon Scutellaria baicalensis Georgi 2.5 0.081
(Scutellariae radix)
kankyo Zingiber officinale Roscoe 2.5 0.081
(Zingiberis Processum Rhizoma)
kanzo Glycyrrhiza uralensis Fischer 2.5 0.081
(Glycyrrhizae Radix) Glycyrrhiza glabra Linné
taiso Ziziphus jujuba Miller var. inermis Rehder 2.5 0.081
(Zizyphi Fructus)
ninjin Panax ginseng C.A. Meyer 2.5 0.081
(Ginseng Radix)
oren Coptis japonica Makino 1.0 0.032
(Coptidis rhizoma) Coptis chinensis Franchet
Coptis deltoidea C. Y. Cheng et Hsiao
Coptis teeta Wallich
total 18.5 0.600
* 7.5 g of hangeshashinto product contains 4.5 g of a dried extract of the mixed crude drugs.
Table 5. The ingredients in the shinbuto (TJ-30) formula.
Japanese Name Scientific Name Amount Amount *(Latin Name) (g) (g/g of Product)
bukuryo Wolfiporia cocos Ryvarden et Gilbertson 4.0 0.089
(Poria Sclerotium) (Poria cocos Wolf)
shakuyaku Paeonia lactiflora Pallas 3.0 0.067
(Paeoniae Radix)
sojutsu Atractylodes lancea De Candolle 3.0 0.067
(Atractylodis Lanceae Rhizoma) Atractylodes schinensis Koidzumi
shokyo Zingiber officinale Roscoe 1.5 0.033
(Zingiberis Rhizoma)
bushi Aconitum carmichaeli Debeaux 0.5 0.011
(Processi Aconiti Radix) Aconitum japonicum Thunberg
total 12.0 0.267
* 7.5 g of shinbuto product contains 2.0 g of a dried extract of the mixed crude drugs.
Table 6. The ingredients in the ninjinto (TJ-32) formula.
Japanese Name Scientific Name Amount Amount *(Latin Name) (g) (g/g of Product)
kankyo Zingiber officinale Roscoe 3.0 0.083
(Zingiberis Processum Rhizoma)
kanzo Glycyrrhiza uralensis Fischer 3.0 0.083
(Glycyrrhizae Radix) Glycyrrhiza glabra Linné
sojutsu Atractylodes lancea De Candolle 3.0 0.083
(Atractylodis Lanceae Rhizoma) Atractylodes schinensis Koidzumi
ninjin Panax ginseng C.A. Meyer 3.0 0.083
(Ginseng Radix)
total 12.0 0.333
* 7.5 g of ninjinto product contains 2.5 g of a dried extract of the mixed crude drugs.
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Table 7. The ingredients in the orento (TJ-120) formula.
Japanese Name Scientific Name Amount Amount *(Latin Name) (g) (g/g of Product)
hange Pinellia ternata Breitenbach 6.0 0.133
(Pinelliae tuber)
oren Coptis japonica Makino 3.0 0.067
(Coptidis rhizoma) Coptis chinensis Franchet
Coptis deltoidea C. Y. Cheng et Hsiao
Coptis teeta Wallich
kankyo Zingiber officinale Roscoe 3.0 0.067
(Zingiberis Processum Rhizoma)
kanzo Glycyrrhiza uralensis Fischer 3.0 0.067
(Glycyrrhizae Radix) Glycyrrhiza glabra Linné
keihi Cinnamomum cassia Blume 3.0 0.067
(Cinnamomi Cortex)
taiso Ziziphus jujuba Miller var. inermis Rehder 3.0 0.067
(Zizyphi Fructus)
ninjin Panax ginseng C.A. Meyer 3.0 0.067
(Ginseng Radix)
total 24.0 0.533
* 7.5 g of orento product contains 4.0 g of a dried extract of the mixed crude drugs.
Table 8. Major ingredients in herbs and their mechanism against arachidonic acid cascade.
Herb Ingredients Mechanisms References
shokyo/kankyo gingerol, shogaol inhibition of COX-2 activity [49,50]
suppression of COX-2 expression [7,51–54]
suppression of NF-κB activation [52–56]
inhibition of PLA2 activity [57]
kanzo glycyrrhizin suppression of COX-2 expression [58–60]
suppression of NF-κB activation [61]
inhibition of TLR4 homodimerization [62]
isoliquiritigenin suppression of COX-2 expression [58,63,64]
suppression of NF-κB activation [64]
inhibition of TLR4 homodimerization [62]
liquiritin suppression of COX-2 expression [58]
keihi cinnamic aldehyde suppression of COX-2 expression [65,66]
suppression of NF-κB activation [67]
inhibition of COX-activity [68]
inhibition of TLR4 oligomerization [69]
ogon baicalin suppression of COX-2 expression [7,70]
suppression of NF-κB activation [70]
baicalein suppression of COX-2 expression [7,71]
suppression of NF-κB activation [72]
wogonin suppression of COX-2 expression [7,73,74]
suppression of MAPK (a) phosphorylation [7]
oren berberin suppression of COX-2 expression [75]
suppression of NF-κB activation [75]
suppression of MAPK (a) phosphorylation [76–79]
enhancement of AMPK (b) [76–78]
(a) MAP kinases; (b) AMP-activated protein kinase.
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3.4.1. Shokyo (Zingiberis Rhizoma)/Kankyo (Zingiberis Processum Rhizoma)
Shokyo is the powdered rhizome of Zingiber offinale Roscoe (ginger), and kankyo is the steamed
and powdered rhizome of ginger. Both shokyo and kankyo are the aqueous extracts of ginger. Among
the herbal medicines shown in Table 1, shokyo is included in kakkonto (TJ-1), shosaikoto (TJ-9),
shinbuto (TJ-30), saireito (TJ-114), and orento (TJ-120), and kankyo is included in hangeshashinto
(TJ-14) and ninjinto (TJ-32). Many reports have demonstrated that ginger possesses anti-inflammatory
effects in human [80,81] and animal models [82–84], and in vitro [85]. Ginger has been widely used in
diet and as a treatment for rheumatoid arthritis, fever, emesis, nausea, and migraine headache [80].
A recent systematic review shows that the extracts of ginger including turmeric, ginger, Javanese ginger,
and galangal are clinically effective as hypoanalgesic agents [81]. In an animal model, the aqueous
extract of ginger significantly reduced serum PGE2 level by oral or intraperitoneal administration
in rats [82]. Moreover, crude hydroalcoholic extract of ginger reduced the serum level of PGE2,
and improved tracheal hyperreactivity and lung inflammation induced by LPS in rats [83]. Ethanol
extract of ginger reduced the tissue level of PGE2, and improved acetic acid-induced ulcerative colitis
in rats [84].
Gingerols and shogaols are the major ingredients in ginger. Their structures are indicated in
Figure 5. With prolonged storage or heat-treatment of ginger, gingerols are converted to shogaols,
which are the dehydrated form of the gingerols [80] (Figure 5). Therefore, kankyo contains a larger
amount of shogaols than shokyo although both shokyo and kankyo contain gingerols and shogaols.
In in vitro models, gingerols and shogaols have been reported to reduce PGE2 production by several
mechanisms. The effects of gingerols and shogaols on arachidonic acid cascade are briefly summarized
in Table 8.
1. Gingerols and shogaols inhibit COX-2 activity. Their IC50 values were µM order: 6-gingerol
(>50 µM), 8-gingerol (10.0 µM), 10-gingerol (3.7 µM), 6-shogaol (2.1 µM), and 8-shogaol (7.2 µM)
in human lung adenocarcinoma A549 cells [49], and 10-gingerol (32.0 µM), 8-shogaol (17.5 µM),
10-shogaol (7.5 µM) in a cell-free assay [50].
2. Gingerols and shogaols suppress COX-2 expression. For example, 6-, 8-, and 10-gingerol
suppressed COX-2 expression in LPS-treated human leukemic monocyte lymphoma U937
cells [51]. Similarly, 6-gingerol and 6-shogaol suppressed LPS-induced COX-2 expression in
mouse macrophage RAW264.7 cells [52], mouse microglial BV-2 cells [53], and primary rat
astrocytes [86]. 6-Gingerol suppressed COX-2 expression in TPA-treated mouse skin in vivo [54].
3. As aforementioned, the expression of COX-2 is regulated by NF-κB. Gingerols and shogaols are
reported to suppress NF-κB activation, and to downregulate COX-2 expression. For example,
6-shogaol suppressed LPS-induced NF-κB activation in RAW264.7 cells [52], mouse primary
cultured microglia cells [53], and human breast cancer MDA-MB-231 cells [56]. 6-Shogaol
suppressed TPA-induced NF-κB activation in mouse skin [54]. Similarly, 6-gingerol suppressed
Vibrio cholerae-induced NF-κB activation in human intestinal epithelial cells [55]. These results
suggest that gingerols and shogaols suppress NF-κB activation directly or indirectly, leading to
the inhibition of COX-2 expression.
4. Gingerols and shogaols inhibit PLA2 activities [57]. In more detail, iPLA2 activity was inhibited
by 6-, 8-, and 10-gingerol and 6-, 8-, and 10-shogaol, whereas cPLA2 activity was inhibited by
6-gingerol and 6-, 8-, and 10-shogaol. In particular, IC50 values of 10-shogaol against iPLA2 and
cPLA2 were 0.7 µM and 3 µM, respectively, in U937 cells.
Medicines 2018, 5, 122 12 of 24
Figure 5. The structures of ingredients in shokyo (Zingiberis Rhizoma) and kankyo (Zingiberis
Processum Rhizoma).
As aforementioned, many reports have examined the effects of ginger. However, there is little
report using ginger as “shokyo” and “kankyo.” For this reason, we examined the mechanism of the
actions of shokyo and kankyo on the reduction of PGE2 production in HGFs. Shokyo and kankyo
concentration-dependently reduced LPS-induced PGE2 production by HGFs, and the effects of kankyo
were slightly stronger than those of shokyo (Figure 4) [39]. The effects of shokyo and kankyo on
arachidonic cascade in HGFs are described as follows.
• Both shokyo and kankyo only slightly increased cPLA2 expression, and did not alter annexin1
expression [39].
• Shokyo did not alter LPS-induced ERK phosphorylation in HGFs [29] (but we have not examined
the effect of kankyo). Therefore, shokyo (and perhaps kankyo) may have little to no effect on
cPLA2 activation, and the subsequent arachidonic acid production.
• Both shokyo and kankyo did not inhibit COX-2 and PGE synthase activities, and did not alter
LPS-induced COX-2 expression in HGFs [29,39]. These findings suggest shokyo and kankyo
primarily inhibit cPLA2 activity in HGFs. Although we have no direct data to show that shokyo
and kankyo inhibit cPLA2 activity, this assumption is consistent with the results that ginger
(and gingerols/shogaols) inhibits both iPLA2 and cPLA2 activities [57].
As described above, our data that shokyo did not alter COX-2 activity and COX-2 expression
are different from those of gingerols and shogaols in Table 8. Although there is no obvious evidence,
the reason may be the preparation method of shokyo and kankyo. Gingerols and shogaols are extremely
hydrophobic by their structures. These ingredients were extracted from hydrophobic phase, whereas
shokyo and kankyo were prepared by decoction. Therefore, hydrophobic ingredients such as gingerol
and shogaol are unlikely to be extracted, and their concentration might be lower than those in previous
reports. Quantification of these ingredients is needed to explain these discrepancies.
3.4.2. Kanzo (Glycyrrhizae Radix)
Kanzo is the powdered root or stolon of Glycyrrhiza uralensis Fischer (licorice). Among the herbal
medicines shown in Table 1, kanzo is included in kakkonto (TJ-1), shosaikoto (TJ-9), hangeshashinto
(TJ-14), ninjinto (TJ-32), rikkosan (TJ-110), saireito (TJ-114), and orento (TJ-120). Licorice is also known
to have anti-inflammatory effects [87] such as inhibition of COX-2 activity [46].
Licorice contains triperpene saponin such as glycyrrhizin (glycyrrhizin acid), and chalcones such
as liquiritin and isoliquiritigenin. Their structures are indicated in Figure 6. Glycyrrhizin, liquiritin,
and isoliquiritigenin are reported to reduce PGE2 production. The effects of these ingredients on
arachidonic acid cascade are briefly summarized in Table 8.
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1. Glycyrrhizin suppressed COX-2 expression in LPS-treated mouse microglial BV2 cells [58] and
uterus of ovariectominezed mice [59]. Moreover, orally administrated glycyrrhizin suppressed
COX-2 expression in the cerebral cortex of LPS-treated mice [60]. Liquiritin and isoliquiritigenin
also suppressed LPS-induced COX-2 expression in RAW264.7 cells [63] and BV2 cells [58].
2. Glycyrrhizin suppressed TNF-α or IL-1β-induced NF-κB activation in human lung epithelial
A549 cells [61]. Isoliquiritigenin also suppressed NF-κB activity and suppressed LPS-induced
COX-2 expression in RAW264.7 cells [64].
3. Glycyrrhizin and isoliquiritigenin inhibited TLR4 (receptor of LPS) homodimerization and
downstream signal pathway [62], resulting in the suppression of COX-2 expression.
Figure 6. The structures of ingredients in kanzo (Glycyrrhizae Radix) and keihi (Cinnamomi Cortex).
Indeed, although glycyrrhizin has anti-inflammatory effects, glycyrrhizin is known to show a
serious adverse effect, pseudohyperaldosteronism. Excessive dietary intake of licorice can cause
a syndrome mimicking hypermineralocorticoidism, characterized by hypertension, hypokalemia,
alkalosis, and reduced plasma renin [88–91]. Glycyrrhizin inhibits 11β-hydroxysteroid dehydrogenase
type 2 (11β-HSD2), which converts active glucocorticoid cortisol to inactive cortisone [92].
This inhibition results in the activation of renal mineralocorticoid receptors by cortisol, inducing Na+
reabsorption, K+ excretion, hypertension, hypokalemia, and metabolic alkalosis. These phenotypes are
similar to that of apparent mineralocorticoid excess syndrome. [91,93].
We examined the mechanism of the action of kanzo on the reduction of PGE2 production in HGFs.
However, the effects of kanzo on arachidonic acid cascade in HGFs cannot be explained by those of
glycyrrhizin, liquiritin, and isoliquiritigenin.
• As reported previously [46], kanzo inhibited COX-2 activity because kanzo decreased
LPS-induced PGE2 production when arachidonic acid was added [29]. In contrast, kanzo did not
inhibit PGE synthase activity because kanzo did not alter LPS-induced PGE2 production when
PGH2 was added [29].
• Kanzo increased both cPLA2 and annexin1 expressions [29], thus leaving the effect of kanzo on
PLA2 unconcluded.
• Kanzo increased LPS-induced COX-2 expression [29] although glycyrrhizin, liquiritin,
and isoliquiritigenin suppressed COX-2 expression [58–60,63,64].
This result is the same as those observed using orento [40] and saireito [44], which contain kanzo.
Therefore, these effects of kanzo were different from those of glycyrrhizin, liquiritin,
and isoliquiritigenin, suggesting that other ingredients may contribute to our findings. In addition,
not all herbal medicines which contain kanzo increased annexin1 as kakkonto, hangeshashinto,
and orento did not alter annexin1 expression.
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3.4.3. Keihi (Cinnamomi Cortex)
Keihi is the powdered bark of Cinnamomum cassia (cinnamon). Among the herbal medicines
shown in Table 1, keihi is included in kakkonto (TJ-1), saireito (TJ-114), and orento (TJ-120). Cinnamon
has been widely used for the treatment of fever and inflammation [28]. Cinnamon improves nephritis,
purulent dermatitis, and hypertension, and it also enhances wound healing. Cinnamon extracts have
been used for the improvement or prevention of common cold, diarrhea, and pain [28]. Ethanol-extract
of C. cassia reduced LPS-induced PGE2 production by RAW264.7 cells, and it suppressed NF-κB activity
and the following COX-2 expression [66].
Keihi contains the ingredients such as cinnamic aldehyde, cinnamic alcohol, cinnamic acid, and
coumarin. The structure of cinnamic aldehyde is indicated in Figure 6. Cinnamic aldehyde is reported
to reduce PGE2 production. The effects of cinnamic aldehyde on arachidonic acid cascade are briefly
summarized in Table 8.
1. Cinnamic aldehyde suppressed carrageenan-induced COX-2 expression and improved footpad
edema in mice [65]. Cinnamic aldehyde, but not others, suppressed LPS-induced COX-2
expression and decreased PGE2 production by RAW264.7 cells [65,66].
2. Cinnamic aldehyde suppressed LPS-induced NF-κB activity in RAW264.7 cells and TLR4-
expressing HEK293 cells [67].
3. Cinnamic aldehyde inhibited IL-1β-induced COX-2 activity in rat cerebral microvascular
endothelial cells although its effect is weak [68].
4. Cinnamic aldehyde inhibited TLR4 oligomerization and downstream signal pathway, which include
NF-κB. Sulfhydryl modification is suggested to be an important contributing factor for the
regulation of TLR4 activation [69].
We examined the mechanism of action of keihi on the reduction of PGE2 production in HGFs.
However, the effects of keihi on arachidonic acid cascade in HGFs cannot be explained by that of
cinnamic aldehyde.
• Keihi inhibited COX-2 activity because keihi decreased LPS-induced PGE2 production when
arachidonic acid is added [29]. This mechanism is accounted for by that of cinnamic aldehyde.
In contrast, keihi did not inhibit PGE synthase activity as well as kanzo.
• As well as kakkonto [81] and orento [40], keihi suppressed ERK phosphorylation in LPS-treated
HGFs [29], leading to inhibit cPLA2 activation. However, the contribution of suppression of ERK
phosphorylation is considered to be small because the ability of keihi to decrease LPS-induced
PGE2 production was weak (Figure 3).
• Keihi increased LPS-induced COX-2 expression.
Therefore, these effects of keihi are different from that of cinnamic aldehyde, suggesting that other
ingredients may contribute to our findings.
3.4.4. Ogon (Scutellariae Radix)
Ogon is the powdered root of Scutellaria baicalensis Georgi. Among the herbal medicines shown in
Table 1, ogon is included in shosaikoto (TJ-9), hangeshashinto (TJ-14), and saireito (TJ-114). Among
the herbs constituting saireito, ogon is reported to reduce PGE2 production by LPS-treated RAW264.7
cells [44].
The major ingredients of ogon are flavonoids such as baicalin, baicalein, and wogonin. Their
structures are indicated in Figure 7. Baicalin is the glucuronide of baicalein and is an inactive
form. Administered baicalein is metabolized to baicalin, which is an active form. Baicalin, baicalein,
and wogonin reduce PGE2 production in human oral keratinocytes [7] and RAW264.7 cells [94].
1. Wogonin suppressed LPS-induced COX-2 expression in RAW264.7 cells [73,74], whereas baicalin
and baicalein did not [73]. Other group demonstrated that baicalein (but not baicalin) suppressed
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LPS-induced COX-2 expression in RAW264.7 cells [71]. This discrepancy may be due to the
concentrations of LPS and flavonoids among these reports. Moreover, baicalein and wogonin
suppressed COX-2 expression in human oral keratinocytes [7].
2. Baicalin [70], baicalein [72], and wogonin [7] suppressed NF-κB activity.
3. Baicalin, baicalein, and wogonin did not inhibit COX-2 activity in RAW264.7 cells [73].
Figure 7. The structures of ingredients in ogon (Scutellariae Radix) and oren (Coptidis Rhizoma).
Our data indicate that shosaikoto and hangeshashinto, which include ogon, suppressed LPS-
induced COX-2 expression in HGFs [37,38]. This mechanism is accounted for by those of baicalin,
baicalein, and wogonin.
3.4.5. Oren (Coptidis Rhizoma)
Oren is the powdered rhizome of Coptis japonica Makino, Coptis chinensis Franchet, Coptis deltoidea
C. Y. Cheng et Hsiao, or Coptis teeta Wallich (Ranunculaceae). Among the herbal medicines shown in
Table 1, oren is included in hangeshashinto (TJ-14) and orento (TJ-120).
Berberine, one of benzylisoquinoline alkaloid, is the major ingredient of oren. The structure of
berberine is indicated in Figure 7. Berberine is reported to reduce PGE2 production. The effects of
berberine on arachidonic acid cascade are briefly summarized in Table 8.
1. Berberine suppressed NF-κB activation and COX-2 expression in human leukemia Jurkat cells [75]
and oral cancer OC2 and KB cells [95,96].
2. Berberine suppressed MAP kinases phosphorylation (including ERK) and activated
AMP-activated protein kinase (AMPK) in peritoneal macrophages and RAW 264.7 cells [76],
BV-2 cells [77], and melanoma cells [78]. Therefore, berberine is considered to inhibit cPLA2
activation through suppression of ERK phosphorylation. In addition, because AMPK is reported
to suppress NF-κB activation [97], berberine suppressed COX-2 expression due to activation
of AMPK.
3.5. Conclusion about Herbal Medicines and Herbs
We have described the effects of herbal medicines, herbs, and their ingredients on arachidonic
acid cascade in this review. Several herbal medicines show reduced LPS-induced PGE2 production
by HGFs. These results suggest that these herbal medicines may be effective in the improvement
of the inflammatory symptoms in periodontitis. Herbal medicines must be properly selected by the
patterns of each patient —excess patterns, medium patterns, or deficiency patterns. Among the herbal
medicines in our studies, kakkonto (TJ-1) and orento (TJ-120) are used for the patients with excess
patterns. Shosaikoto (TJ-9), hangeshashinto (TJ-14), and orento are used for the patients with medium
patterns. Shinbuto (TJ-30) and ninjinto (TJ-32) are used for the patients with deficiency patterns.
Therefore, it may be possible to use appropriate herbal medicines to patients with any pattern.
As shown in the above-mentioned descriptions, not all effects of herbal medicines are explainable
by the effects of herbs constituting herbal medicines. Similarly, not all effects of herbs are explainable
by the effects of ingredients contained in herbs. Experiments using “herbal medicines” or “herbs”
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themselves may be important rather than those using ingredients. The concentrations of these
hydrophobic ingredients may also be low because the herbs that we used are water-soluble fractions.
Therefore, it is considered that the concentrations of their ingredients need to be measured. Moreover,
the unanalyzed ingredients other than those explained in this review are likely to be present. It is to be
desired that further analyses reveal the novel ingredients and their action of mechanisms.
4. Anti-Osteoclastogenic Effects of Natural Products
Like periodontitis (PD), rheumatoid arthritis (RA) is a disease associated with inflammation and
bone destruction. Although therapeutics of RA have recently advanced with the development of
antibody drugs, natural substances displaying anti-inflammatory and anti-osteoclast characteristics
against RA are still being used as widely as they have been in the past.
Some studies have revealed a relationship between PD and RA. RA prevalence is increased in
patients with PD [98,99]. The presence of PD may contribute to the progression of RA; that is, RA
patients with PD receiving non-surgical periodontal treatment resulted in a noteworthy improvement
in the clinical outcome for RA [100]. From the aspect of the clinical marker, RA and PD are similar in
cytokines and mediators involved in inflammation and bone destruction [101]. For example, TNF-α,
receptor activator of nuclear factor-κB ligand (RANKL), and matrix metalloproteinase (MMP) family
increase in production in RA and PD [102–106]. Due to these similarities, natural products used for
RA are probably effective for PD.
The structures of natural products described in this review are indicated in Figure 8.
Figure 8. The structures of natural products.
Epidemiological studies have revealed a positive correlation between bone health and increased
consumption of fruits and vegetables [107,108]. Some fruits and vegetables contain components that
inhibit both inflammation and osteoclast activity.
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β-Cryptoxanthin is a carotenoid present in a wide range of citrus fruits and in Diospyros kaki
Thunb., Physalis alkekengi L., etc. β-Cryptoxanthin has a potent inhibitory effect on osteoclast-like
cell formation in mouse marrow culture [109]. Moreover, in a mouse model of PD, β-cryptoxanthin
suppressed bone resorption in the mandibular alveolar bone in vitro and restored alveolar bone loss
induced by LPS in vivo [110].
Naringenin is a flavonoid contained in citrus fruits such as oranges and grapefruits. Accumulating
evidence has suggested that naringenin modulates chronic inflammation [111]. In a murine model of
collagen-induced arthritis, naringenin inhibited pro-inflammatory cytokine production by decreasing
MAPK and NF-κB signaling activation [112]. La et al. showed naringenin thus holds promise as a
therapeutic and preventive agent for bone-related diseases such as PD [113]. Thus, there are cases in
which components demonstrating anti-osteoclast behavior are demonstrated to be effective against PD.
In addition to naringenin, citrus fruits contain components that suppress osteoclast activity via MAPK.
Nomilin, a limonoid present in citrus fruits, displays inhibitory effects on osteoclastic differentiation
through the suppression of MAPK signaling pathways [114].
Ellagic acid is a polyphenol contained in berries, pomegranates, nuts, etc. Ellagic acid
has an anti-inflammatory effect in various organs such as the liver, stomach, small intestine,
and skin [115–118]. Moreover, ellagic acid has anti-osteoclast activity and significantly reduced serum
levels of pro-inflammatory cytokines, TNF-α, IL-1β, and IL-17 in RA model mice [119]. A recent study
supported the traditional use of Geum urbanum L. root contained ellagic acid derivatives in cavity
inflammation including mucositis, gingivitis, and PD [120].
Additional useful components against both RA and PD have been found in tea.
(-)-Epigallocatechin-3-gallate (EGCG) is a major catechin derivative present in green tea. Previous
studies have also suggested that EGCG decreases MMP-1, MMP-2, and MMP-3 production by RA
synovial fibroblasts, thereby preventing further cartilage and bone destruction [121,122]. Moreover,
it has been reported that EGCG selectively inhibited IL-1β-induced IL-6 synthesis in RA synovial
fibroblasts and suppressed IL-6 trans-signaling via upregulation of an endogenous inhibitor, a soluble
gp130 [123]. Clinical study of EGCG suggested that local drug delivery utilizing green tea extract
could be used as an adjunct in the treatment of chronic PD [124].
Traditional medicine in Ayurveda also presents useful teas against RA and PD. Salacia reticulata
Wight is a plant native to Sri Lanka that has been used for the prevention of RA, gonorrhea, and skin
disease. We previously reported that leaf of S. reticulata alleviates collagen antibody-induced arthritis in
RA model mice [125]. S. reticulata contains a polyphenol known as mangiferin that inhibits osteoclastic
bone resorption by promoting ERβ mRNA expression in mouse bone marrow macrophage cells [126].
In conclusion, natural products displaying both anti-inflammation and anti-osteoclast
characteristics are suggested to be useful for the prevention and treatment of PD.
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